Clinical Trial

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Name: Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases — clinical trial record (NCT07511933)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-03-30.

Trial Details

NCT Number	NCT07511933
Lead Sponsor	The Netherlands Cancer Institute
Conditions	Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Melanoma, Brain Metastases From Breast Cancer
Enrollment	100 participants
Start Date	2019-12-24
Primary Completion	2027-01-01 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-24